|
Agenta |
Class |
Dosage |
Adverse effects |
|
Etanercept |
TNF-alpha inhibitor |
50 mg SC twice weekly for 12 weeks, then 50 mg every week |
– Injection-site reaction – Increased risk of upper and lower respiratory tract infection – TB and hepatitis B reactivation – Increased risk of malignancy and lymphomas – Drug-induced lupus – Demyelinating disease – Worsening of heart failure |
|
Adalimumab |
TNF-alpha inhibitor |
80 mg SC at week 0, 40 mg at week 1, and then 40 mg every 2 weeks |
– Injection-site reaction – Increased risk of upper and lower respiratory tract infection – TB and hepatitis B reactivation – Increased risk of malignancy and lymphomas – Drug-induced lupus – Demyelinating disease – Worsening of heart failure |
|
Infliximab |
TNF-alpha inhibitor |
5 mg/kg IV at weeks 0, 2, and 6, and then every 12 weeks |
– Infusion reactions – Increased risk of upper and lower respiratory tract infection – TB and hepatitis B reactivation – Increased risk of malignancy and lymphomas – Drug-induced lupus – Demyelinating disease – Worsening of heart failure |
|
Certolizumab pegol |
TNF-alpha inhibitor |
400 mg SC every 2 weeks |
– Injection-site reaction – Increased risk of upper and lower respiratory tract infection – TB and hepatitis B reactivation – Increased risk of malignancy and lymphomas – Drug-induced lupus – Demyelinating disease – Worsening of heart failure |
|
Ustekinumab |
IL-12/23 inhibitor |
45 mg (weight <100 kg) or 90 mg (weight >100 kg) SC at weeks 0 and 4, then the same dose every 12 weeks |
– Injection-site reaction – Increased risk of upper respiratory tract infection – Headache |
|
Secukinumab |
IL-17 inhibitor |
300 mg SC at weeks 0, 1, 2, 3, and 4, then every 4 weeks |
– Injection-site pain and reaction – Increased risk of infection with Candida spp – Neutropenia – IBD |
|
Ixekizumab |
IL-17 inhibitor |
160 mg SC at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks |
– Injection-site pain and reaction – Increased risk of infection with Candida spp – Neutropenia – IBD |
|
Brodalumab |
IL-17 inhibitor |
210 mg SC at weeks 0, 1, and 2, and then every 2 weeks |
– Injection-site pain and reaction – Increased risk of infection with Candida spp – Neutropenia – IBD – Depression and suicidal ideation |
|
Guselkumab |
IL-23 inhibitor |
100 mg SC at weeks 0 and 4, and every 8 weeks thereafter |
– Injection-site reaction – Increased risk of upper respiratory tract infection – Headache |
|
Risankizumab |
IL-23 inhibitor |
150 mg SC at weeks 0 and 4, and every 12 weeks thereafter |
– Injection-site reaction – Increased risk of upper respiratory tract infection – Headache |
|
Tildrakizumab |
IL-23 inhibitor |
100 mg SC at weeks 0 and 4, and every 12 weeks thereafter |
– Injection-site reaction – Increased risk of upper respiratory tract infection – Headache |
|
a Baseline screening for latent TB and hepatitis B and C is recommended before initiation of treatment with any of these agents. | |||
|
IBD, inflammatory bowel disease; IL, interleukin; TB, tuberculosis; TNF, tumor necrosis factor; SC, subcutaneous; spp, species. | |||